Abstract | BACKGROUND: New antiplatelet agents that provide greater, more consistent inhibition of the platelet ADP receptor P2Y12 may be used in combination with glycoprotein ( GP) IIb-IIIa antagonists, but their combined effect on platelet function and procoagulant activity is not well studied. Therefore, the objective of this study was to evaluate the independent and complementary effects of P2Y12 and GPIIb-IIIa inhibition on platelet function and procoagulant activity. METHODS AND RESULTS: CONCLUSIONS: The complementary effects of abciximab and R-138727 on platelet activation, aggregation, and procoagulant activity suggest their combined use may, to a greater degree than with either agent alone, reduce thrombus formation in vivo.
|
Authors | Michelle A Berny-Lang, Joseph A Jakubowski, Atsuhiro Sugidachi, Marc R Barnard, Alan D Michelson, Andrew L Frelinger 3rd |
Journal | Journal of the American Heart Association
(J Am Heart Assoc)
Vol. 2
Issue 3
Pg. e000026
(May 15 2013)
ISSN: 2047-9980 [Electronic] England |
PMID | 23676293
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Immunoglobulin Fab Fragments
- P2RY12 protein, human
- Peptides
- Piperazines
- Platelet Aggregation Inhibitors
- Platelet Glycoprotein GPIIb-IIIa Complex
- R-138727
- Receptors, Purinergic P2Y12
- Eptifibatide
- Abciximab
|
Topics |
- Abciximab
- Antibodies, Monoclonal
(pharmacology)
- Blood Platelets
(drug effects, physiology)
- Eptifibatide
- Humans
- Immunoglobulin Fab Fragments
(pharmacology)
- Peptides
(pharmacology)
- Piperazines
(pharmacology)
- Platelet Activation
(drug effects)
- Platelet Aggregation
(drug effects)
- Platelet Aggregation Inhibitors
(pharmacology)
- Platelet Glycoprotein GPIIb-IIIa Complex
(antagonists & inhibitors)
- Receptors, Purinergic P2Y12
(drug effects)
|